The power of protein degradation is now being realized. This innate cellular process is responsible for maintaining protein homeostasis, and we are now exploiting it to break down the proteins that cause disease. The protein degradation opportunity is immense and reaches across a broad range of disease areas in which new and enhanced treatments are needed. Development of the best, most effective medicines for patients requires extensive biology insight, medicinal chemistry experience, drug discovery expertise and cutting-edge computational tools such as artificial intelligence and machine learning. Proteovant is leveraging targeted protein degradation to discover and develop transformative medicines for the treatment of patients with life-altering diseases.
Philadelphia, United States
Founded in 2021
11-50 Employees
Startup
Working industry
Biotechnology
Type of company
-
Ownership structure
Privately Held
Locations
1 Headquarter
Specialised areas
Biotechnology, biopharma, immunology, oncology, neurology, protein degradation
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
United States
Overall risk estimation:
Low
The ESG Data of countries are based on public sources
Environment
D
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
A
Grade (A-E)
View details
Proteovant Therapeutics operates in 1 country around the world
Get an overview of the locations of Proteovant Therapeutics
Location
Country
State
City
Headquarter
United States
Pennsylvania
Philadelphia
Some frequent questions that have been asked about Proteovant Therapeutics
Where is Proteovant Therapeutics located?
The company headquarter of Proteovant Therapeutics is located in Philadelphia, Pennsylvania, United States. It's worth noting, that the company may have more locations
How many employees does Proteovant Therapeutics approximately have?
As of the latest available information Proteovant Therapeutics has around 11-50 employees worldwide.
When was Proteovant Therapeutics founded?
Proteovant Therapeutics was founded in 2021
In which industries does Proteovant Therapeutics mainly work?
The company Proteovant Therapeutics has it's main focus in the industries of Biotechnology
What is the current company status of Proteovant Therapeutics?
Based on the founding year and the amount of employees the company Proteovant Therapeutics seems to be a Startup at the current state. Note that over time that status can change
Check out some interesting alternative companies to Proteovant Therapeutics
16250 - 1st TPD Europe 2020
London, United Kingdom
1-10 Employees
-
As the industry consolidates pipelines and heads out of a turbulent 2023 market, the targeted protein degradation engine has shown no signs of slowing. Our blossoming community of degrader experts are inspiring each other to develop medicines to address patients’ unmet medical needs. Dedicated to Progressing the Field with Groundbreaking Research.
Orum Therapeutics
Kazan, Russia
11-50 Employees
2016
We are pioneering a class of therapeutics intended to expand the universe of druggable targets and to meaningfully improve upon potency and tolerability, and thereby improve the therapeutic window of drugs. Our goal is to bring life-changing therapies to patients by combining the power of the emerging field of protein degraders with the precision of antibodies to generate a broad portfolio of highly differentiated product candidates. A portfolio of highly differentiated products combining the power of protein degraders with the precision of antibodies.
PAQ Therapeutics
Cambridge, United States
1-10 Employees
2020
We are developing a new class of small molecule degradation therapies by expanding the ability to directly target and eliminate disease-causing entities beyond proteins. PAQ’s expert team of global scientists, entrepreneurs and world-class scientific advisors are committed to broadening therapeutic horizons driven by advances in autophagy.
Lycia Therapeutics
San Diego, United States
11-50 Employees
2019
To that end, we are advancing an undisclosed discovery pipeline of novel LYTAC degraders toward the clinic. We are also eligible to receive over $1.6 billion in potential milestone payments based on the achievement of prespecified preclinical, development and commercial milestones, as well as tiered royalties from mid-single to low double-digits on sales resulting from the agreement. We are leveraging the flexibility of our platform to pursue targets previously considered undruggable, opening the potential for new therapeutics options for patients. We are building a stellar team, driven to pioneer breakthrough science and motivated to make a difference for patients. Protein degradation offers the potential to eliminate disease-causing proteins. The mannose-6-phosphate receptor (M6PR) is a cell-surface glycoprotein that acts as a lysosomal trafficking shuttle.
Progenra
Malvern, United States
11-50 Employees
2002
Progenra’s mission is to leverage its expertise in the ubiquitin proteasome system, Molecular Glues and PROTAC drugs, to discover and develop novel, first in class medicines to fill unmet needs in a spectrum of therapeutic areas. Progenra’s mission is to leverage its expertise in the ubiquitin proteasome system, Molecular Glues and, PROTAC drugs to discover and develop novel, first in class medicines to fill unmet needs in a spectrum of therapeutic areas. Its UbiPro™ Drug Discovery Platform is a multi-faceted approach based on the physiological milieux in which enzymes of the ubiquitin proteasome system interact with their substrates. The Ubiquitin Proteasome System as a Therapeutic Area in Parkinson’s Disease Progenra Inc, February 2023 Parkinson’s disease (PD) is the most common neurodegenerative movement disorder.
Intropic Materials
Oakland, United States
1-10 Employees
-
To fix that, we developed nanoprotectants that keep the proteins stable and active in foreign environments. We are currently working on scaling up the technology in order to bring our vision to the world. We’re starting by addressing the plastic waste problem, making self-degrading products that can be composted or perfectly recycled. From self-degrading plastics to clean manufacturing and biosensors, our platform unlocks potential for proteins. Through years of technical development and extensive communication with the plastics ecosystem, we are ready to deliver truly impactful innovation.